News & Publications

 

Find information below

News

”Sune Justesen, CSO at Immunitrack, will be presenting at the Immunotherapy Progress and Clinical Treatment (IMPACT), in San Diego, USA on the 5-7th of December. The topic of his talk will be Stability matters, Neoscreen. For further information on the conference and to register, please press on the link”

Stephan Thorgrimsen, CEO at Immunitrack, will be presenting the NeoscreenTM technology, and its applicability within the field of immuno-oncology at the Department of Chemistry in Cambridge, England on the 26th of October 2017. For further information on the seminar and to register, please press on the link

Sune Justesen, CSO at Immunitrack, will be presenting at Cancer Vaccine on the 28th of September in London. Topic of his talk will be in vitro validation of potential neo-epitopes by MHC based reagents. For further information on the conference and to register, please press on the link

Meet us at the third CRI-CIMT-EATI-AACR international cancer immunotherapy conference, in Mainz Germany on the 6-9th of September 2017

Meet us at the ESMO conference, in Madrid, Spain, on the 8th-12th of September2017. The conference is about Integrating science into oncology for a better patient outcome

Immuno-oncology has become one of the most promising and fastest growing areas of cancer research and drug development – do you have the best science to make the difference? Meet us at Bio-Europe Spring

The CSO of Immunitrack becomes member of the the Association for Cancer Immunotherapy (CIMT)

The Association for Cancer Immunotherapy (CIMT) is a member-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians and regulatory authorities who research and develop cancer immunotherapies. CIMT was founded in 2002 by physicians and researchers from different fields of clinical and theoretical medicine as an independent non-profit organization. CIMT has its offices in Mainz, Germany, and has been financed by donations, congress fees, industry sponsorship and by the following public and foundation grants.

please visit the homepage at www.cimt.eu

Meet us at the 2nd drug discovery Innovation programme on October 20-21 in Hamborg Germany

Bio-Business Seminar - February 2016

February 10th: Immunitrack to give oral presentation at 2016 – 10th Swiss-Scandinavian Bio-Business Seminar

Immunitrack in London March 1st. 2016 - February 2016

Immunitrack invited to give a company presentation at 6th Annual Biologics Symposium – London

BioFit partnering event - December 2015

Immunitrack participates in BioFit partnering event.

Innobooster grant- December 2015

Immunitrack receives an InnoBooster grant from the ministry of innovation and technology

Immunogenicity and Bioassay summit - November 2015

Immunitack participates in annual CHI “Immunogenicity and Bioassay summit” and wins poster competition. Download our PDF


Publications

1
Configuration-dependent presentation of multivalent IL-15:IL-15Rα enhances the antigen-specific T cell response and anti-tumor immunity.
J Biol Chem. 2015 Dec 30. pii: jbc.M115.695304. 
PMID: 26719339 Free Article

2.
Materno-Fetal Transfer of Preproinsulin Through the Neonatal Fc Receptor Prevents Autoimmune Diabetes.
Diabetes. 2015 Oct;64(10):3532-42. doi: 10.2337/db15-0024. 
PMID: 25918233

3.
Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance.
Sci Transl Med. 2015 Feb 18;7(275):275ra21. doi: 10.1126/scitranslmed.aaa1957.
PMID: 25696000

4.
A carbon nanotube-polymer composite for T-cell therapy.
Nat Nanotechnol. 2014 Aug;9(8):639-47. doi: 10.1038/nnano.2014.154. Epub 2014 Aug 3. Erratum in: Nat Nanotechnol. 2014 Sep;9(9):723. Harold, Kevin C 
PMID: 25086604

5.
Identification and HLA-tetramer-validation of human CD4+ and CD8+ T cell responses against HCMV proteins IE1 and IE2.
PLoS One. 2014 Apr 23;9(4):e94892. doi: 10.1371/journal.pone.0094892. eCollection 2014.
PMID: 24760079 Free PMC Article

6.
MHC class II tetramers made from isolated recombinant α and β chains refolded with affinity-tagged peptides.
PLoS One. 2013 Sep 2;8(9):e73648. doi: 10.1371/journal.pone.0073648. eCollection 2013. Erratum in: PLoS One. 2013;8(9).
doi:10.1371/annotation/97cabee9-2a2a-4bd6-a417-a2075e56a8d4. PLoS One. 2013;8(12). doi:10.1371/annotation/9375e7cb-92f1-4a83-adaf-c11f284ceee0.
PMID: 24023895 

7.
Chaperone-assisted thermostability engineering of a soluble T cell receptor using phage display.
Sci Rep. 2013;3:1162. doi: 10.1038/srep01162. Epub 2013 Jan 29.
PMID: 23362461 

8.
Adsorption of multimeric T cell antigens on carbon nanotubes: effect on protein structure and antigen-specific T cell stimulation.
Small. 2013 Mar 11;9(5):666-72. doi: 10.1002/smll.201201684. Epub 2012 Oct 23.
PMID: 23090793

9.
Wildtype p53-specific antibody and T-cell responses in cancer patients.
J Immunother. 2011 Nov-Dec;34(9):629-40. doi: 10.1097/CJI.0b013e3182281381.
PMID: 21989411

10.
Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides.
Immunology. 2011 Apr;132(4):482-91. doi: 10.1111/j.1365-2567.2010.03383.x. Epub 2011 Feb 7.
PMID: 21294723 

11.
NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure.
Immunome Res. 2010 Nov 13;6:9. doi: 10.1186/1745-7580-6-9.
PMID: 21073747 

12.
HLA class I binding 9mer peptides from influenza A virus induce CD4 T cell responses.
PLoS One. 2010 May 7;5(5):e10533. doi: 10.1371/journal.pone.0010533.
PMID: 20479886 

13.
Functional recombinant MHC class II molecules and high-throughput peptide-binding assays.
Immunome Res. 2009 May 5;5:2. doi: 10.1186/1745-7580-5-2.
PMID: 19416502 

14.
Recombinant chymosin used for exact and complete removal of a prochymosin derived fusion tag releasing intact native target protein.
Protein Sci. 2009 May;18(5):1023-32. doi: 10.1002/pro.112.
PMID: 19388053 

15.
Peptide binding to HLA class I molecules: homogenous, high-throughput screening, and affinity assays.
J Biomol Screen. 2009 Feb;14(2):173-80. doi: 10.1177/1087057108329453. Epub 2009 Feb 4.
PMID: 19196700

16.
Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues.
FEBS J. 2008 Aug;275(16):4097-110. doi: 10.1111/j.1742-4658.2008.06551.x. Epub 2008 Jul 15.
PMID: 18637944 

17.
Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan.
PLoS Comput Biol. 2008 Jul 4;4(7):e1000107. doi: 10.1371/journal.pcbi.1000107.
PMID: 18604266 

18.
One-pot, mix-and-read peptide-MHC tetramers.
PLoS One. 2008 Feb 27;3(2):e1678. doi: 10.1371/journal.pone.0001678.
PMID: 18301755 

19.
A strategy for bacterial production of a soluble functional human neonatal Fc receptor.
J Immunol Methods. 2008 Feb 29;331(1-2):39-49. Epub 2007 Dec 10.
PMID: 18155020

20.
NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence.
PLoS One. 2007 Aug 29;2(8):e796.
PMID: 17726526

21.
Crystal structures of two peptide-HLA-B*1501 complexes; structural characterization of the HLA-B62 supertype.
Acta Crystallogr D Biol Crystallogr. 2006 Nov;62(Pt 11):1300-10. Epub 2006 Oct 18.
PMID: 17057332

22.
Fractionation, solid-phase immobilization and chemical degradation of long pectin oligogalacturonides. Initial steps towards sequencing of oligosaccharides.
Carbohydr Res. 2006 Jan 16;341(1):118-29. Epub 2005 Nov 17.
PMID: 16297890

23.
Fractionation of whey proteins with high-capacity superparamagnetic ion-exchangers.
J Biotechnol. 2004 Sep 30;113(1-3):247-62.
PMID: 15380659

24.
Definition of supertypes for HLA molecules using clustering of specificity matrices.
Immunogenetics. 2004 Mar;55(12):797-810. Epub 2004 Feb 13.
PMID: 14963618

NEWSLETTER

Do you wish to receive our newsletter?
Click here

CONTACT US